+28.1%
ECL vs GSK
+46.9%
-18.8%
-43.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.4% | -2.7% | +2.3% | +0.3% |
| 7D | -0.8% | -4.2% | +3.4% | +0.3% |
| 30D | -2.5% | -7.5% | +5.0% | -0.5% |
| 3M | +8.3% | -3.3% | +11.6% | +9.2% |
| 6M | -1.1% | -9.3% | +8.2% | +1.3% |
| YTD | +6.5% | +1.6% | +4.9% | +6.1% |
| 1Y | +2.1% | +25.5% | -23.4% | -3.9% |
| 3Y | +57.6% | +49.3% | +8.3% | +39.2% |
| 5Y | +28.1% | +46.7% | -18.6% | +9.3% |
| All | +28.1% | +46.9% | -18.8% | +9.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling